Company ProfilePremium

Cellivery Therapeutics, Inc.

Company Profile Analysis

Ticker: 268600.KQ주식회사 셀리버리

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cellivery Therapeutics, Inc. - Company showcase

Year Founded & Workforce

2014

9 Employees

Cellivery Therapeutics, Inc. logo

Cellivery Therapeutics, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cellivery Therapeutics, Inc. Overview

Cellivery Therapeutics was founded in 2014 as a platform biotech built around a protein-delivery technology originally called MITT (Macromolecule Intracellular Transduction Technology) and later rebranded TSDT (Therapeutic Molecule Systemic Delivery Technology), which the company claimed could carry large recombinant proteins across cell membranes and the blood-brain barrier. In November 2018 it became the first company admitted to KOSDAQ under the underwriter-recommended "growth special listing" track, and during the COVID-19 period its market value briefly exceeded KRW 3 trillion on expectations for its Parkinson's candidate iCP-Parkin and anti-inflammatory iCP-NI. No candidate advanced beyond an early Phase 1 trial and no external licensing deal was ever disclosed. After diverting capital-markets proceeds into the acquisition of a wet-tissue maker, the company received consecutive audit disclaimers, was delisted in March 2025, and is now a near-dormant unlisted entity controlled by former minority shareholders.


What the company did (as designed). Cellivery positioned itself as a drug-delivery platform company. Its core claim was that by fusing therapeutic proteins with engineered peptide sequences, it could produce "cell-permeable" recombinant proteins (branded iCP- or CP-) able to enter cells and tissues, including deep brain tissue, which conventional biologics cannot easily reach. Upon IPO in 2018, the prospectus described four protein-based drug candidates — iCP-Parkin (Parkinson's disease), iCP-SOCS3 (pancreatic cancer), CP-BMP2 (bone formation), and CP-ΔSOCS3 (severe obesity) — plus three lines of cell-permeable research reagents (iCP-Cre, six iCP-RF reprogramming factors, and CP-Cas9) (Dailypharm, 9 Nov 2018, citing the investment prospectus).

Business model and revenue model. The intended model was a classic platform-licensing model: (i) out-license individual candidates after preclinical or early clinical proof-of-concept, (ii) non-exclusively license the TSDT platform itself to large pharma partners, and (iii) fund R&D partly through sales of research reagents. In 2017 the company reported revenue of KRW 2.7 bn, operating loss of KRW 3.4 bn and net loss of KRW 3.5 bn, with reagent sales described as a source of self-generated R&D funding (BioSpectator, Sept 2018). In 2016 revenue was KRW 1.3 bn, which management attributed to licensing-related activity (Kormedi report on MJFF grant).

What the company actually became. From November 2021 the revenue base changed fundamentally. Cellivery acquired 100% of Ajin Clean, a wet-tissue and hygiene-products maker founded in 1991, for KRW 14.9 bn, injected a further KRW 14.0 bn of capital, and renamed it Cellivery Living & Health (BizWatch, 18 Jul 2022; Economist Korea, 5 Apr 2023). From FY2022, essentially all consolidated revenue came from this consumer subsidiary (cosmetics, hygiene and lifestyle goods). The parent company's separate revenue was zero in FY2023 and again zero in FY2024 (Dailypharm, 5 Jun 2024; MTN, 21 Feb 2025).

Revenue mix (independent characterisation).

Value-chain position. Pre-2021: discovery and preclinical research, with manufacturing (CMC) and all GLP toxicology and clinical work outsourced to CROs/CMOs in the US, Europe and Asia (Covance/Labcorp, Southern Research, OPIS, KBI). Post-2021: additionally a domestic consumer-goods manufacturer and retailer through the subsidiary.

Customer types and end-markets. Intended: global pharmaceutical companies as licensees (neurology, oncology, immunology/infectious disease). Actual: academic and industrial labs (reagents) and Korean retail consumers (Living & Health products via department stores, duty-free and a flagship store; the premium brand later withdrew from department-store and duty-free channels per Economist Korea, Apr 2023).

Company's own description. The latest annual report language is not available in the sources reviewed. Third-party aggregators summarise the company as developing protein, small-molecule, antibody and vaccine drugs primarily for South Korea, holding US-registered patents, and operating Cellivery Living & Health in beauty and health since January 2022 (roic.ai company profile).

Current operating state (2025–2026). Following delisting, the company is controlled by shareholders who removed the founder. Public reporting in 2026 focuses on the criminal case against former management rather than on any resumed R&D. No active clinical programme, partnership or product revenue at parent level has been publicly disclosed since 2023.

Strategy

Historic stated strategy (2018–2022). Management repeatedly framed the strategy as monetising TSDT through (i) candidate out-licensing, (ii) non-exclusive platform licensing to big pharma, and (iii) fast-tracking iCP-NI into Phase 2 and emergency-use pathways. In October 2019 the CEO told investors he expected a platform deal comparable to or exceeding the Dicerna–Eli Lilly RNAi platform deal (Dealsite, 10 Oct 2019). In 2020 he said an iCP-Parkin licence could be worth trillions of won and a TSDT licence over KRW 1 trillion (Asia Economy, May 2020). None of these deals materialised.

Diversification (2021–2023). Acquisition of Ajin Clean and creation of Cellivery Living & Health, licensing TSDT intra-group for cosmetics and lifestyle products, with a KRW 20 bn annual-revenue target. Prosecutors argued — and the court accepted at first instance — that this pivot was in part a response to the growth-special-listing rule under which a company with annual revenue below KRW 3 bn from its fifth listed year is designated an administrative issue (Bizhankook, Jun 2026).

Survival measures (2023–2024). Objection to delisting and improvement period; promised "normal" trading resumption; claimed negotiations with multiple investors conditional on resolving the governance dispute and extending the improvement period (NewDaily, Mar 2024); addition of automotive-parts trading to business purposes (Etoday, Aug 2024); consideration of winding down Living & Health (Economist Korea, Apr 2023).

Post-delisting strategy (2025–2026). The shareholder-led management's publicly visible priorities have been (i) pursuing criminal and civil accountability of former management, and (ii) preserving the company as an unlisted going concern. Shareholder statements during liquidation trading indicated an intention to accumulate more shares to consolidate control (MTN, Feb 2025). In 2024 the coalition stated a plan to normalise operations and then recruit professional management (NewDaily, Mar 2024). No formal medium-term business plan, R&D restart, financial targets or ESG commitments have been publicly disclosed.

Management guidance / medium-term targets: None publicly disclosed.

Products & Services

5A. Platform technology

MITT → TSDT (Therapeutic Molecule Systemic Delivery Technology). Originally described as Macromolecule Intracellular Transduction Technology (MITT), later branded TSDT; the "TSDT" trademark dates from 2018 (IPqwery). Company claims: enables recombinant proteins to penetrate cell membranes and to pass sequentially cell-to-cell, including across vascular endothelium into brain tissue. The CEO stated at IPO that the technology was the product of roughly 20 years of personal research (BizWatch, Oct 2018). Pricing model: intended licence fees, milestones and royalties; no third-party platform licence ever disclosed.

5B. Drug candidates (by therapeutic area)

CandidateModality / mechanism (company description)Indication(s)Highest stage reachedPartners / notesKey dates
iCP-ParkinCell-permeable recombinant Parkin proteinParkinson's disease; later claimed Alzheimer's and oncology utilityPreclinical; CMC scale-up at KBI (US CMO) reported 2021Co-developed with Ildong Pharmaceutical; MJFF-funded MoA study; patents in AU, EU, JPScience Advances paper Apr 2020; JP patent Feb 2020
iCP-NICell-permeable protein immunomodulator targeting innate immune/cytokine-storm signallingCOVID-19 severe pneumonia, sepsis, atopic dermatitis, ARDS; inhaled formulation planned for mild COVIDPhase 1 (healthy volunteers) — trial NCT05740280 shows status TerminatedCROs: Covance (tox), Southern Research (efficacy), OPIS (EU/India), Labcorp (US IND)EU CTA Poland 6 Sep 2021; FDA IND filed 9 Sep 2022, cleared Oct 2022
iCP-SOCS3Cell-permeable SOCS3 proteinPancreatic cancerPreclinical (primate safety reviewed by prospective licensee)China rights negotiated with Qilu Pharmaceutical (2019–2020); no deal announced—
CP-FXNCell-permeable frataxin proteinFriedreich's ataxiaPreclinical (animal efficacy under milestone 3)Takeda co-development (from Nov 2018); no licence announcedMilestone 3 contract Jul 2019
CP-BMP2Cell- and tissue-permeable bone morphogenetic protein (bio-better)Bone formation / fracturesPreclinicalEP patent 38 countriesAug 2020
CP-ΔSOCS3 / CP-SDTruncated SOCS3 SH2-domain proteinSevere obesityPreclinicalPatent family filed 2021—

5C. Research reagents (product revenue line pre-2022)

ProductDescriptionStatus
iCP-CreCell-permeable Cre recombinase for gene-editing researchMarketed pre-IPO; current status not disclosed
iCP-RFs (6 products)Cell-permeable reprogramming factorsMarketed pre-IPO; current status not disclosed
CP-Cas9Cell-permeable Cas9In development at IPO

5D. Consumer products (Cellivery Living & Health)

LineDescriptionStatus
Wet tissues / hygiene goodsLegacy Ajin Clean manufacturing business (est. 1991)Ongoing at last report; subsidiary capital-impaired
The Lafuse (더 라퓨즈)Premium cosmetics brand marketed with TSDT positioningWithdrew from department stores and duty-free (Apr 2023)
Celli LoungeFlagship store, Garosu-gil, Gangnam, SeoulOpened 2022; continuity uncertain (Apr 2023)
Bioneul (바이오늘)Lifestyle/health business lineDescribed as uncertain (Apr 2023)
Health functional foodsPlanned entry from 2023No evidence of launch

Pricing models for consumer products: not publicly disclosed. Target annual revenue of KRW 20 bn was stated by management in January 2022 (Dailypharm related headline; Dealsite related headline).

Financial Narrative

Data quality warning. FY2019–FY2021 figures are from audited statements; FY2022 and FY2023 statements carry disclaimers of opinion (audit scope limitation, going-concern uncertainty, and questions over the appropriateness of investment and fund transactions). FY2024 consolidated annual figures and FY2025 statements are not publicly available in the sources reviewed. All figures are consolidated, IFRS, KRW millions unless stated. Primary aggregator: Stockopedia (sourced from annual audited accounts).

6A. Income statement

Operating income FY2019–FY2022 by year: not publicly disclosed in sources reviewed; cumulative consolidated operating loss FY2021–FY2023 was KRW 114.5 bn, implying combined FY2021+FY2022 operating losses of approximately KRW 94.9 bn (Dailypharm, 5 Jun 2024).

Gross profit, EBITDA, EPS (basic/diluted), dividends per share: not publicly disclosed in sources reviewed. Dividends: none ever paid.

6B. Margins (computed from 6A)

Revenue CAGR FY2019–FY2023: approx. 73.7% per year, computed. This figure is not indicative of organic growth: the step-change in FY2022 reflects consolidation of the acquired wet-tissue business, while parent-level pharmaceutical revenue fell to zero.

6C. Trailing-twelve-month trajectory

Note the internal inconsistency in the aggregator series (LTM revenue at Sep-2023 of KRW 39.1 bn exceeding the FY2023 total of KRW 18.9 bn), which likely reflects restatement or reclassification within disclaimed statements. Both figures are shown as reported; the discrepancy is unresolved.

6E. Cash flow and capital raising

Pre-IPO and IPO funding (KRW bn).

PitchBook additionally lists PIPE transactions dated 19 Aug 2020, 1 Oct 2021, and 15 Oct 2021 (the last at USD 16.5 m) and cumulative funding of USD 74.2 m.

6F. Ratios

ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle: not meaningful / not publicly disclosed. Equity approached zero by mid-2023 and EBITDA was persistently negative, rendering leverage and return ratios mathematically meaningless. Simply Wall St reports return on equity as "n/a".

6G. Commentary

The five-year record shows a pre-revenue biotech whose losses roughly doubled from FY2020 to FY2021 and then more than doubled again in FY2022 to a net loss of KRW 75.2 bn, the inflection coinciding with the pandemic-era equity surge, aggressive stock-option exercises, the capital raise of September 2021, and the consolidation of a loss-making consumer subsidiary. The FY2022 spike in general and administrative expense (LTM KRW 44.4 bn versus R&D of KRW 19.1 bn per Simply Wall St) indicates that the cost base grew far more on overhead and the subsidiary than on research. FY2023 losses contracted to KRW 32.6 bn largely because the organisation was dismantled: headcount went from 100 to 9 within a year, and the parent generated no revenue. By the September 2024 LTM point, net losses were down to KRW 6.1 bn on revenue of KRW 8.8 bn, a shrinkage consistent with wind-down rather than recovery. The company's revenue never came from its claimed core technology in any meaningful, third-party-validated way.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Units

UnitLegal entityContentsStatus

Pharmaceutical R&D (parent)

Cellivery Therapeutics, Inc.

TSDT platform, drug candidates (iCP-Parkin, iCP-NI, iCP-SOCS3, CP-FXN, CP-BMP2, CP-ΔSOCS3), research reagents

Separate revenue zero in FY2023 and FY2024; no tangible assets beyond fixtures reported by early 2025 (MTN)

Consumer / Living & Health

Cellivery Living & Health Co., Ltd. (formerly Ajin Clean, est. 1991)

Wet tissues, hygiene products, cosmetics ("The Lafuse"), flagship store "Celli Lounge", planned health-functional foods; "Bioneul" business line

100% owned at acquisition; fully capital-impaired; FY2022 operating loss KRW 28.5 bn and net loss KRW 30.6 bn; FY2022 audit disclaimed (Economist Korea, Apr 2023)

Revenue by Segment

MetricFY2021FY2022FY2023

Consolidated revenue (KRW Mn)

3,87223,15818,863

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Revenue

MetricFY2023FY2024

Parent-company separate revenue (KRW Mn)

00

Income Statement

MetricFY2019FY2020FY2021FY2022FY2023

Revenue (KRW Mn)

2,0747623,87223,15818,863

Pre-tax income (KRW Mn)

-19,577-17,937-29,682-75,018-34,007

Net income after taxes (KRW Mn)

-19,650-17,248-28,069-75,159-34,036

Net income attributable to owners (KRW Mn)

-19,650-17,248-28,069-75,159-32,571

Metric

FY2023

————

Consolidated operating income (KRW Mn)

-19,600————

Parent separate operating income (KRW Mn)

-11,900————

Margin Analysis (%)

MetricFY2019FY2020FY2021FY2022FY2023

Pre-tax margin (%)

-943.9-2,354.0-766.6-323.9-180.3

Net margin attributable (%)

-947.4-2,263.5-724.9-324.6-172.7

Metric

FY2023

————

Operating margin consolidated (%)

-103.9————

Income Statement (Dec-2021–Sep-2024)

MetricDec-2021Mar-2022Jun-2022Sep-2022Dec-2022Mar-2023Jun-2023Sep-2023Dec-2023Mar-2024Jun-2024Sep-2024

LTM revenue (KRW Mn)

3,8724,0084,2234,30623,15830,45734,99439,13018,86314,49411,1938,831

LTM net income (KRW Mn)

-28,069-31,276-32,762-30,831-75,159-82,316-85,507-83,317-32,571-20,314-9,429-6,127

Financial Analysis

ItemLatest disclosed data pointSource

Cash & equivalents

Defence counsel stated the company had about KRW 45 bn of liquid assets in Sept 2021; prosecution stated only about KRW 7.2 bn was in ordinary deposits, the rest tied in short-term instruments

Bizhankook, Jun 2026

Total debt

Convertible bonds outstanding with put option exposure of approx. KRW 35 bn cited as a factor in the FY2022 disclaimer

MT, 13 Oct 2023

Equity

H1 2023 equity below KRW 1 bn; capital impairment ratio ≥50%

Dealsite, 23 Aug 2023

Tangible assets (parent)

By early 2025 consisted only of office fixtures

MTN, 21 Feb 2025

Buybacks

None identified

—

Equity/convertible raised Sept 2021

Approx. KRW 69.9–70 bn via convertible bonds and related issuance, disclosed for R&D; court found funds were used for Ajin Clean acquisition and related purposes

MTN; Bizhankook 2026

Unsecured loans to subsidiary

Approx. KRW 20.3 bn lent to Living & Health without collateral

MTN, Jun 2026

Capital injection into subsidiary

KRW 14.0 bn

BizWatch 2022

Round Details

RoundYearAmount (KRW Bn)Key investors

Series A

20155.0

SBI Investment, CKD Venture Capital, Platinum Technology Investment

Series B

20178.5

Ildong Pharmaceutical, Dongbu Securities, SBI Investment

Pre-IPO

20187.0

Not itemised

IPO

2018

Up to 28.4 at KRW 25,000/share (band implied KRW 22.7–28.4 bn)

Public; lead manager DB Financial Investment

Revenue by Region

RegionFY2021FY2022FY2023

South Korea — consolidated revenue, inferred (KRW Mn)

3,87223,15818,863

Market Valuation

Metric2020-01-022020-08-132021-01-282023-03-232025-03

Market capitalisation (KRW Bn)

484.81,0003,142.3244.32

Share Price

MetricIPO Nov 20182020-04-012023-03 suspension2025-03 post-liquidation

Share price (KRW)

25,00084,7006,68060

Capital Markets

ItemStatus

Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B)

Not meaningful (negative earnings and equity; no market price)

Analyst consensus

None; aggregators report zero analysts

Dividend history and policy

No dividends ever paid

Buyback authorisations

None identified

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

Not publicly disclosed; CB put exposure approx. KRW 35 bn referenced in 2023

Unlisted-market status

Seoul Exchange trading support terminated pending prior-year audit report

Analyst Conclusions

Management guidance. None publicly disclosed since the April 2025 change of control.

Consensus growth expectations. None; no analyst coverage.

Bull case (low probability)

  1. IP monetisation: If the iCP-Parkin and iCP-SOCS3 patent families remain in force, a sale to a delivery-platform developer could return some value to an equity base of 37.2 m shares that currently has no market price.

  2. Recoveries from former management: A first-instance conviction (Aug 2026) accepting that approx. KRW 70 bn was misused strengthens the company's standing to pursue civil recovery against convicted executives.

  3. Cost discipline under shareholder control: Losses had already contracted to an LTM KRW 6.1 bn by Sept 2024; an aligned owner-manager may run the shell at minimal cost while pursuing recoveries and asset sales.

Bear case (base case)

  1. No operating business at parent: Separate revenue of zero in FY2023 and FY2024 and a staff of single digits mean there is no R&D engine to restart.

  2. Liabilities and subsidiary losses: A capital-impaired subsidiary, unsecured intra-group loans of KRW 20.3 bn, and historic CB obligations point toward restructuring or liquidation rather than revival.

  3. Recoveries likely limited: The court cut forfeiture from the KRW 67.7 bn sought to about KRW 0.5 bn, and the large fines accrue to the state, not the company; competing claims from ~50,000 shareholders further dilute any recovery.

Catalysts and monitorables (next 12 months)

  • Whether Cho and Kwon appeal, and the appellate timeline at the Seoul High Court.

  • Filing of FY2025 audited financial statements (required for resumption of unlisted trading on Seoul Exchange).

  • Status of the patent estate (maintenance, assignment, encumbrance).

  • Disposition of Cellivery Living & Health (sale, liquidation or rehabilitation).

  • Outcomes of shareholder civil suits and any corporate damages claim against former officers.

  • Any formal insolvency or rehabilitation filing by the parent.

Analyst verdict

Cellivery Therapeutics is no longer an investable operating company; it is a post-delisting legal and asset-recovery situation. Its history is a case study in how a pre-revenue platform biotech can reach a multi-trillion-won valuation on press-released preclinical claims and unnamed partnership discussions without ever producing a third-party licence or meaningful clinical data. Between its November 2018 listing as the first growth-special-listing company and its March 2025 delisting, the company's only material revenue came from a wet-tissue and cosmetics business acquired in November 2021 — an acquisition that a Korean court has now found, at first instance, was funded with roughly KRW 70 bn raised from investors on the representation that it would finance drug development.

The quantitative record supports this reading. General and administrative expense exceeded R&D in every year with data, peaking at KRW 44.4 bn against KRW 19.1 bn of R&D in FY2022. Net losses reached KRW 75.2 bn in FY2022, and the two subsequent annual audits ended in disclaimers. Headcount fell from 100 to 9 within twelve months, and parent revenue fell to zero.

The April 2025 transfer of control to the minority shareholders' coalition and the August 2026 conviction of the founder close the governance chapter but do not restore an enterprise. The remaining value, if any, lies in the patent estate, possible civil recoveries, and the disposal of the consumer subsidiary — each uncertain in existence, timing and magnitude, and none disclosed in auditable form. Absent a credible audited FY2025 balance sheet and a disclosed plan for the IP, the rational base case is that equity holders recover little or nothing. For market participants and policymakers, Cellivery's enduring significance is as the precedent behind Korea's 2025 tightening of delisting rules and the heightened scrutiny of special-listing biotech disclosures.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground

Yoon Ju-won (윤주원)

CEO / Representative Director

Since April 2025 EGM

Leader of the Cellivery minority shareholders' coalition (2,772 shareholders, 26.41% stake in 2024–25); a retail shareholder who stated his retirement savings were tied up in the stock

Board of Directors

NameFormer roleNotes

Cho Dae-woong (조대웅)

Founder, CEO, largest shareholder (13.32% personally; 13.88% with related parties as of Mar 2024)

Convicted at first instance 20 Aug 2026: 15 years' imprisonment, KRW 210 bn fine, forfeiture of approx. KRW 517.28 m; bail revoked and detained in court.

Kwon Seon-hong (권선홍)

Former CFO / inside director

Convicted at first instance 20 Aug 2026: 5 years, KRW 110 bn fine

Kim Hyung (김형)

Head of Strategic Planning; elected inside director at 29 Mar 2024 AGM

Current status not disclosed

Baek Yung-ki (sources also spell "Park Yung-ki")

Outside director; removal proposed by shareholders Mar 2024

Name spelling discrepancy between NewDaily and Hankyung reports

Lee Jae-man (이재만)

Described as second-largest shareholder; briefly a non-standing management adviser; shareholder-nominated director candidate in 2024

NewDaily, Mar 2024

Unnamed "Executive Choi"

Former registered executive (resigned Apr 2021)

Received KRW 23.6 bn in H1 2021 compensation, of which KRW 23.48 bn was stock-option exercise gain (Dailypharm)

Unnamed "Executive Kwon"

Executive

KRW 2.03 bn stock-option gain in H1 2021

Unnamed "Auditor Lee"

Statutory auditor

KRW 1.01 bn stock-option gain in H1 2021

Unnamed former Vice President

Former VP

Summarily indicted Oct 2023 alongside Cho

Major Shareholders

HolderStakeDate / source

Minority shareholders' coalition (aggregated proxies)

26.41% (2,772 members)

MTN, Feb 2025; NewDaily, May 2024

Cho Dae-woong

13.32%

NewDaily, Mar 2024

Cho + related parties

13.88%

NewDaily, Mar 2024

Cho and spouse shares subject to forced liquidation (margin calls)

Approx. 5.1 m shares expected to be sold in liquidation trading

MTN, Feb 2025

Pre-IPO institutions (SBI Investment, CKD VC, NH Investment & Securities, Korea Securities Finance, Dongbu Securities)

38.6% combined

NewDaily, Sept 2018 (historic)

Total shareholders

Approx. 50,000, claiming aggregate losses above KRW 1 trillion

Bizhankook, Jun 2026

Competitive Landscape

Competitors by Segment

ArenaNamed competitorsRelative positioning vs Cellivery

BBB shuttle / brain delivery platforms

Roche (Brainshuttle), Denali Therapeutics (Transport Vehicle), ABL Bio (Grabody-B, Korea)

Competitors validated platforms via clinical data and/or licensing deals with large pharma; Cellivery's claims remained preclinical and unpartnered

Intracellular delivery of large molecules

Entrada Therapeutics (EEV), PepGen (EDO), Sarepta (PPMO), Dicerna (RNAi platform, licensed to Eli Lilly — cited by Cellivery's CEO as benchmark)

Competitors reached human trials or major platform deals

Korean platform biotechs

Alteogen (subcutaneous formulation platform), LigaChem Biosciences (ADC platform), ABL Bio

All achieved multi-billion-dollar global licensing; Cellivery achieved none

Parkinson's disease-modifying

Roche/Prothena (prasinezumab), Biogen (cinpanemab), Kainos Medicine (Korea)

Cellivery itself noted both antibodies failed Phase 2 (MT, May 2021); Cellivery never entered clinic for Parkinson's

COVID-19 / cytokine storm

Dexamethasone (standard of care), Roche (tocilizumab), Eli Lilly (baricitinib)

Approved agents dominated; iCP-NI Phase 1 terminated

Korean special-listing biotech cohort (failed)

PharmAbcine, Olipass (both delisted 2025)

Same fate; Cellivery was first

Recent Developments

Because the strict 18-month window (April 2025 – October 2026) contains limited corporate activity, the register is extended back to March 2023 to capture the full sequence of material events.

Appeal filings following the 20 August 2026 verdict: not confirmed in sources reviewed.

Company Snapshot

$14.4M

Revenue

9

Employees

2014

Founded

SWOT Analysis

Strengths

  • Patent estate: Granted patent families on iCP-Parkin in Australia, the EU and Japan, and an EP patent on a cell-permeable bone-formation promoter covering 38 countries (Dealsite, Feb & Aug 2020) — the main potentially monetisable residual asset, subject to verification of current status.
  • Peer-reviewed publication: iCP-Parkin data published in Science Advances (April 2020), providing a citable scientific record.
  • Regulatory documentation: An FDA-cleared IND for iCP-NI (October 2022) and a completed EU CTA filing (Poland, Sept 2021) demonstrate that a regulatory dossier package once existed.
  • Engaged shareholder base: A coalition of 2,772 holders representing 26.41% organised and ultimately took control, now led by CEO Yoon Ju-won (MTN 2025; Bizhankook 2026).
  • Clean break from former management: The founder has been convicted and detained (20 Aug 2026), removing the governance overhang from the entity's control.
  • Small cost base: LTM net loss had shrunk to KRW 6.1 bn by Sept 2024 (Simply Wall St), reducing cash burn.

Weaknesses

  • No parent revenue: Separate revenue of zero in FY2023 and FY2024 (Dailypharm; MTN).
  • Two consecutive audit disclaimers: FY2022 and FY2023, citing scope limitation and going-concern uncertainty.
  • Capital impairment: Equity below KRW 1 bn and ≥50% impairment by H1 2023 (Dealsite).
  • Loss-making subsidiary: Living & Health posted FY2022 operating loss of KRW 28.5 bn and is fully capital-impaired (Economist Korea).
  • No external validation: Not a single disclosed third-party licence across the listed life despite repeated public claims of imminent deals (Dealsite 2019–2020).

Opportunities

  • IP monetisation: Sale or licensing of the patent estate to a delivery-platform company could recover some value.
  • Civil recovery: The criminal conviction supports civil damages claims against former management by the company and shareholders.
  • Subsidiary disposal: Divesting or liquidating Living & Health could stop losses (considered by management in April 2023).
  • Fine-and-forfeiture enforcement: The court imposed fines of KRW 210 bn and KRW 110 bn on the two former executives; any recoverable assets may be contested by creditors and victims (enforcement mechanics not disclosed).
  • Unlisted-market re-quotation: Seoul Exchange states trading can resume once a prior-year audit report is confirmed, offering a liquidity path for shareholders.
  • Scientific interest in brain-delivery modalities: Large pharma continues to invest in BBB delivery, sustaining at least theoretical demand for related IP.

Threats

  • Insolvency risk: No operating revenue at parent, residual CB obligations (put exposure approx. KRW 35 bn cited in 2023), and an impaired subsidiary.
  • Litigation drag: Appeals in the criminal case may extend for years, delaying civil recovery.
  • Patent lapse: Without funds, maintenance fees and prosecution may lapse, eroding the main residual asset.
  • Regulatory tightening: January 2025 delisting reform raises the bar for any relisting.
  • Reputational contamination: The "first growth-special listing" brand is now associated with fraud in Korean media and courts.
  • Creditor claims: Unsecured intra-group loans (KRW 20.3 bn) to a capital-impaired subsidiary may be unrecoverable.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
23 Mar 2023Last trading day before suspension; market cap KRW 244.3 bnStart of 2-year suspension
Mar 2023Disclaimer of opinion on FY2022 consolidated and separate statementsDelisting cause triggered
31 Mar 2023CEO kneels before shareholders at AGM, promising resumption of tradingReputational turning point
5 Apr 2023Living & Health also receives audit disclaimer; parent weighs winding it downSubsidiary going-concern failure
10 Apr 2023KRX publishes Cellivery among KOSDAQ companies with new delisting causesFormal process begins
Apr 2023Objection filed; one-year improvement period grantedTemporary reprieve
21 Aug 2023CEO issues status report promising normal trading resumptionShareholder management
22 Aug 2023H1 2023 review disclaimed; investment-caution reasons added (≥50% capital impairment, equity < KRW 1 bn)Second delisting route opens
Sep 2023Shareholders' coalition files criminal complaint (Capital Markets Act, aggravated breach of trust and fraud)Beginning of criminal track
26 Oct 2023Coalition seeks injunction suspending CEO and former VP from director dutiesGovernance contest
27 Oct 2023CEO and former VP summarily indicted on a separate workplace sexual misconduct charge–
13 Mar 2024Shareholder-requisitioned EGM fails to convene; CEO declares items rejectedContested legality
29 Mar 2024AGM held after nine-hour delay; management proposal electing Kim Hyung passes; coalition proxies via ACT platform (25.6%) not fully recognisedManagement retains control
Mar 2024FY2023 statements disclaimed (second consecutive year)Delisting virtually certain
29 May 2024Coalition files opinion with KRX requesting improvement period instead of delistingLast-ditch appeal
3 Jun 2024KRX Corporate Review Committee resolves to delistDelisting decision
4 Jun 2024Company files injunction at Seoul Southern District Court; liquidation trading suspendedDelay
1 Aug 2024Company to add automotive-parts sales to business purposesAttempt to create revenue
17 Feb 2025Cho Dae-woong indicted (fraudulent unfair trading, false statement of material facts)Criminal case begins
21 Feb 2025Court dismisses injunctionDelisting resumes
25 Feb – 6 Mar 2025Liquidation trading; price collapses toward KRW 60Equity value effectively wiped out
7 Mar 2025Delisted from KOSDAQ — first biotech delisting in about 12 yearsMarket-structure precedent
Apr 2025EGM installs Yoon Ju-won as CEOChange of control to shareholders
May 2025Media frame Cellivery and PharmAbcine as start of a biotech delisting wave under tightened rulesSector context
Jul 2025Court grants Cho bail during trialProcedural
Oct 2025Olipass follows Cellivery and PharmAbcine out of KOSDAQ; sector-wide scrutiny of special-listing biotechsSector context
11 Jun 2026Prosecutors seek 30 years, KRW 250 bn fine and KRW 67.7 bn joint forfeiture for Cho; 7 years for co-defendantSeverity of case
20 Aug 2026First-instance verdict: Cho 15 years, KRW 210 bn fine, approx. KRW 517 m forfeiture, detained; ex-CFO Kwon 5 years, KRW 110 bn fineCourt accepts diversion of R&D funds
2025–2026 (date not disclosed)Seoul Exchange ends trading support for Cellivery pending audit reportNo functioning secondary market

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Consolidated revenue rose from KRW 3,872 Mn in FY2021 to KRW 18,863 Mn in FY2023.
Cellivery Therapeutics, Inc. — Revenue by Segment
Series (KRW Mn)FY2021FY2022FY2023
Consolidated revenue3,87223,15818,863

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Stockopedia — Cellivery Therapeutics income statement and share price (annual audited accounts FY2019–FY2023; post-liquidation price) · stockopedia.com
  2. Simply Wall St — LTM revenue, earnings, G&A and R&D (Dec 2021 – Sep 2024) (simplywall.st)
  3. roic.ai — company profile and suspension-era price/market cap (roic.ai)
  4. PitchBook — funding history and employee count (pitchbook.com)
  5. Seoul Exchange (unlisted market) — CEO, address, share count, trading status (seoulexchange.kr)
  6. Dailypharm, 5 Jun 2024 — delisting resolution, market cap history, employees, stock options, FY2023 results (dailypharm.com)
  7. Dailypharm, Feb 2025 — liquidation trading and delisting timeline (dailypharm.com)
  8. Dailypharm, 29 May 2025 — biotech delistings and rule tightening (dailypharm.com)
  9. Dailypharm, 27 Oct 2025 — sector delisting wave (dailypharm.com)
  10. Dailypharm, 9 Nov 2018 — IPO prospectus pipeline and pricing (dailypharm.com)
  11. MTN, 21 Feb 2025 — injunction dismissed, indictment, zero separate revenue (news.mtn.co.kr)
  12. MTN, 22 Feb 2025 — shareholder coalition and liquidation trading (news.mtn.co.kr)
  13. MTN, 11 Jun 2026 — prosecution sentencing request (news.mtn.co.kr)
  14. Bizhankook, 11 Jun 2026 — trial hearing, allegations, CEO Yoon appointment (bizhankook.com)
  15. Bizhankook, 20 Aug 2026 — first-instance verdict (bizhankook.com)
  16. YTN, 11 Jun 2026 — sentencing request and forfeiture amounts (ytn.co.kr)
  17. iNews24 — Q1 2024 revenue and injunction (inews24.com)
  18. Etoday, 1 Aug 2024 — delisting crisis and auto-parts business purpose (etoday.co.kr)
  19. Dealsite, 10 Apr 2023 — KRX delisting causes (dealsite.co.kr)
  20. Dealsite, 23 Aug 2023 — H1 2023 disclaimer and caution designations (dealsite.co.kr)
  21. Economist Korea, 5 Apr 2023 — Living & Health acquisition and losses (economist.co.kr)
  22. BizWatch, 18 Jul 2022 — Living & Health acquisition, capital injection, intra-group licence (news.bizwatch.co.kr)
  23. MT, 13 Oct 2023 — CB put exposure (mt.co.kr)
  24. MT, 7 Nov 2023 — summary indictment and shareholder complaints (mt.co.kr)
  25. NewDaily, 13/18/29 Mar 2024 and 30 May 2024 — general meetings and shareholdings · biz.newdaily.co.kr · biz.newdaily.co.kr
  26. BioSpectator, Sept 2018 — pre-IPO funding, 2017 financials (biospectator.com)
  27. BizWatch, 23 Oct 2018 — IPO details (news.bizwatch.co.kr)
  28. NewDaily, 18 Sept 2018 — DB Financial Investment and pre-IPO holders (biz.newdaily.co.kr)
  29. Dealsite (2019–2020) — Takeda, global top-3 pharma, JPM, patents · dealsite.co.kr · dealsite.co.kr · dealsite.co.kr · dealsite.co.kr
  30. Asia Economy — iCP-NI Covance studies, EU CTA, Science Advances briefing, BBB claims · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr
  31. MT (2021–2022) — OPIS, brain PK, FDA IND filing and clearance, sepsis plans · mt.co.kr · mt.co.kr · mt.co.kr · mt.co.kr · mt.co.kr
  32. ClinicalTrials.gov — NCT05740280 (iCP-NI Phase 1, terminated) (clinicaltrials.gov)
  33. Michael J. Fox Foundation grant page (michaeljfox.org)
  34. Kormedi — MJFF selection (kormedi.com)
  35. IPqwery — patent and trademark families (ipqwery.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.